Relevant bibliographies by topics / Low molecular weight heparin / Books
To see the other types of publications on this topic, follow the link: Low molecular weight heparin.

Books on the topic 'Low molecular weight heparin'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Low molecular weight heparin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Barrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hyers, Thomas M. Treatment handbook of low-molecular-weight heparin. London: Science Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thromoprophylaxis with low-molecular-weight heparins. London: Current Medicine Group, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Christian, Doutremepuich, ed. Low molecular weight heparins in clinical practice. New York: Dekker, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1940-, Kher André, Sarret Monique 1938-, and Toulemonde Francis 1926-, eds. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. New York: Marcel Dekker, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Holmer, Erik. Heparin and its low molecular weight derivatives: Basic and applied studies in the development of a new antithrombotic drug. Uppsala: Sveriges Lantbruksuniversitet, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Maguire, Jacinta Marie. Low molecular weight heparin regime or unfractionated heparin and as pirin in the treatment of unstable angina. [S.l: The Author], 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shukla, Vijay K. Low molecular weight heparins for major orthopedic surgery: A case for clinical outcomes. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527629978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bäckvall, Helena, and Janne Lehtiö, eds. The Low Molecular Weight Proteome. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7209-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Nightingale, Philip D. Low molecular weight halocarbons in seawater. Norwich: University of East Anglia, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Haug, G., and H. Hoffmann, eds. Pyrethroid Residues, Immunoassays for Low Molecular Weight Compounds. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74846-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Blass, W. Pyrethroid residues, immunoassays for low molecular weight compounds. Berlin: Springer-Verlag, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Bäckvall, Helena. The low molecular weight proteome: Methods and protocols. New York: Springer, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Niemelä, Klaus. Low-molecular-weight organic compounds in birch kraft black liquor. Helsinki: Suomalainen Tiedeakatemia, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Zhu, Yibo. Two-dimensional material-based nanosensors for detection of low-molecular-weight molecules. [New York, N.Y.?]: [publisher not identified], 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Astrid, Sigel, and Sigel Helmut, eds. Probing of proteins by metal ions and their low-molecular-weight complexes. New York: Marcel Dekker, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

McCallum, N. K. A specific method for the analysis of low molecular weight phenols using pentafluorobenzyl ethers. Lower Hutt: Chemistry Division, Dept. of Scientific and Industrial Research, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Layton, Guy Timothy. The immunogenicity and allergenicity of low molecular weight chemicals: Chlorhexidine as the model hapten. Birmingham: University of Birmingham, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Pierson, Janice Rose. A study of the expression of the low molecular weight cytokeratins in cervical pearls. [S.l: The Author], 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

L, Newton Gerald, and United States. National Aeronautics and Space Administration., eds. Determination of low molecular weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. [Washington, DC]: National Aeronautics and Space Administration, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Morales, Roman Padilla. High density polyethylene modified with a low molecular weight ionomer and the precursor acid copolymer. Ottawa: National Library of Canada, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Yang, Jaeyoung. Micro and Nanoscale Aptasensors for Detection of Low Molecular Weight Biomarkers Towards Clinical Diagnostic Applications. [New York, N.Y.?]: [publisher not identified], 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Latorre, Sandra Stefanie. Formation of low molecular weight organic compounds from UV disinfection of chlorinated water containing humic substances. Ottawa: National Library of Canada, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Blackwell, Malcolm Peter. Investigation of a biochemical marker of pulmonary eosinophil influx as a predictive assay for low molecular weight respiratory sensitisers. [Derby: University of Derby], 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Kägi, Jeremias H. R., 1930- and Kojima Yutaka 1933-, eds. Metallothionein II: Proceedings of the Second International Meeting on Metallothionein and Other Low Molecular Weight Metal-binding Proteins : Zürich, August 21-24, 1985. Basel: Birkhäuser Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Laturnus, Frank. Bildung und Abgabe kurzkettiger halogenierter Kohlenwasserstoffe durch Makroalgen der Polarregionen =: Formation and release of low-molecular weight halogenated hydrocarbons by macroalgae from polar regions. Bremerhaven: Alfred-Wegener-Institut für Polar- und Meeresforschung, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Low Molecular Weight Haparins. 3rd ed. BC Decker Inc., 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Samama, Meyer M. Low Molecular Weight Heparin and Its Clinical Use: Journal: Haemostasis, Vol. 16, 1985 (Low Molecular Weight Heparin & Its Clinical Use). S. Karger AG (Switzerland), 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Low Molecular Weight Heparins. Decker Periodicals, Canada, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Breddin, H. K. Low Molecular Weight Heparins. S Karger AG, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Power, Trevor David. Derivatization of low molecular weight heparin with polyethylene glycol monomethyl ether (MPEG). 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Sarret/Kher/tou. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Informa Healthcare, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
34

Sarret, Monique, Andre Kher, and Francis Toulemonde. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Taylor & Francis Group, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: M. Dekker, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Kakkar, V. V. Low-Molecular-Weight Heparins - New Fronteirs in Antithrombotic Therapy (Haemostasis). S Karger Pub, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Low-Molecular-Weight Heparins: A New Therapeutic Approach to Thrombosis Proceedings (Journal - Haemostasis , Vol 26, Suppl. 2). S. Karger AG (Switzerland), 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

MacCallum, Niall S. Management of oncological complications in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0376.

Full text
Abstract:
Important treatment complications relevant to critical care are discussed. Cancer-related pain is complex and requires multidisciplinary care, particularly in the peri-operative setting. Chemotherapeutic complications include pancytopenia, cardiac, pulmonary, renal, gastrointestinal, hepatic, and neurotoxicity. Radiotherapy complications include cardiac, pulmonary, and gastrointestinal toxicity. In general, management includes assessing the risk-benefit to cytotoxic therapy withdrawal and supportive care. There is a paucity of proven treatment options for most complications, althoughcertain therapies are used to prevent and/or treat complications (e.g. tumour lysis syndrome). Thromboembolic disease is a common cause of mortality and morbidity; low molecular weight heparin therapy may be superior to oral anticoagulation.
APA, Harvard, Vancouver, ISO, and other styles
39

Peppelenbosch, A. G., and Martijn Poeze. Ischaemic bowel in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0186.

Full text
Abstract:
Intestinal ischaemia is caused by occlusion of the visceral arteries, thrombosis of the mesenteric veins, or by (low-flow) non-occlusive mesenteric ischaemia (NOMI). Each condition has a specific diagnostic and therapeutic work-up and prognostic significance. The incidence of acute mesenteric infarction is as low as 0.63 cases/100,000 person years, but overall mortality rates remains high at 74%. In general, a high index of suspicion is necessary and should be followed by administering therapeutic low molecular weight heparin or systemic heparin infusion. In these patients resuscitation and organ support are essential, but should not delay diagnostic work-up, including CT-angiography. With arterial occlusion, revascularization should be performed if indicated, preferentially using endovascular techniques prior to laparotomy. For venous occlusion, thrombolytic therapy directly into the superior mesenteric artery or venous thrombectomy can be performed, followed by laparotomy. The treatment of NOMI is to treat the underlying cause.
APA, Harvard, Vancouver, ISO, and other styles
40

Kilkelly, Shannon. Coagulation System. Edited by Matthew D. McEvoy and Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0090.

Full text
Abstract:
Despite the development of entirely new classes of anticoagulant medication, vitamin K antagonists like warfarin continue to be commonly prescribed for a wide range of cardiovascular diagnoses. Conversely, the advent of low molecular weight heparin has greatly simplified the use of the drug to the point that patients can dose themselves at home with no need for any type of monitoring. Given the widespread use of these medications, it is not surprising that an increasing number of patients requiring urgent or emergent surgery will present with a medically induced coagulopathy. Managing this coagulopathy requires assessment of the urgency of the operation, the patient’s volume status, and the need for reanticoagulation following surgical intervention.
APA, Harvard, Vancouver, ISO, and other styles
41

Low Molecular Weight Organic Semiconductors. Vch Verlagsgesellschaft Mbh, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
42

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Limited, John, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Chong, Ji Y., and Michael P. Lerario. Cancer and Coagulopathy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190495541.003.0019.

Full text
Abstract:
Advanced cancer is well known to cause a procoagulant state. The formation of sterile platelet thrombin vegetations on cardiac valves (i.e., nonbacterial thromboembolic disease) and arterial thrombosis are common etiologies of stroke in these patients. Despite preventative therapy with antiplatelet agents or low-molecular-weight heparins, stroke in cancer often portends a poor prognosis.
APA, Harvard, Vancouver, ISO, and other styles
47

Ballal, Salma, and Ian A. Greer. Thromboembolic disorders in pregnancy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713333.003.0037.

Full text
Abstract:
Thromboembolism in pregnancy remains a major cause of direct maternal mortality in the Western world. Thromboembolic events in pregnancy are spread across the three trimesters but the puerperium is the time of greatest risk with a relative risk of around 20-fold compared to the non-pregnant patient. When compared to the non-pregnant population where distal deep vein thrombosis is most common, most events in pregnancy are iliofemoral and left sided. Given the multi-hit nature of the problem, awareness of risk factors is important. The two most significant single risk factors in pregnancy for thromboembolism are history of previous venous thromboembolism and thrombophilia. The identification of risk factors will guide the use of thromboprophylaxis and assist diagnosis; however, objective diagnosis is required. Prophylaxis and treatment focuses on low-molecular-weight heparin, which is considered safe in pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
48

Bäckvall, Helena, and Janne Lehtiö. Low Molecular Weight Proteome: Methods and Protocols. Springer New York, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Zemskov, V. M. Immunomodulating Effects of a Low Molecular Weight RNA. Routledge, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Hayden, John. Low molecular weight organic acids in forest soils. 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Low molecular weight heparin' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography